Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus‐specific cytotoxic T lymphocytes

Primary Cytomegalovirus (CMV) infection and reactivation of persistent CMV are associated with significant morbidity and mortality in immuno‐compromised individuals. Although recovery from CMV disease is correlated with the development of CMV‐specific cytotoxic T lymphocytes (CTL), the major viral target antigens to which the response is directed are ill‐defined, though they may comprise viral structural elements. We now identify the CMV matrix protein pp65 as a significant target antigen for CD8+ class I major histocompatibility complex (MHC)‐restricted CMV‐specific CTL derived from the peripheral blood of four of five latently infected individuals. CMV‐specific CTL recognition of pp65 on target cells occurs prior to the onset of viral gene expression and persists throughout the duration of the replicative cycle. Recognition in the absence of viral gene expression suggests that abundant viral protein enters the normal trafficking pathway upon viral penetration and is readily made available to MHC molecules for presentation at the cell surface. Thus pp65 specific CTL may represent an important effector population for early control and limitation of CMV infection and disease. The observation that CMV‐specific CTL can be induced in vitro using peptide fragments derived from pp65 supports the future use and manipulation of this and similar effector populations in a clinical setting. © 1994 Wiley‐Liss, Inc.

[1]  S. Riddell,et al.  Development of a Treatment Regimen for Human Cytomegalovirus (CMV) Infection in Bone Marrow Transplantation Recipients by Adoptive Transfer of Donor‐Derived CMV‐Specific T Cell Clones Expanded In Vitro a , 1991, Annals of the New York Academy of Sciences.

[2]  S. Riddell,et al.  Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. , 1991, Blood.

[3]  W. Britt,et al.  Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. , 1991, Journal of immunology.

[4]  S. Riddell,et al.  The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. , 1990, Journal of immunological methods.

[5]  U. Koszinowski,et al.  Cellular and molecular basis of the protective immune response to cytomegalovirus infection. , 1990, Current topics in microbiology and immunology.

[6]  H. Rammensee,et al.  In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine , 1989, Nature.

[7]  H. Ljunggren,et al.  Association of class I major histocompatibility heavy and light chains induced by viral peptides , 1989, Nature.

[8]  J. Rothman GTP and methionine bristles , 1989, Nature.

[9]  J. Bonifacino,et al.  Brefeldin A implicates egress from endoplasmic reticulum in class I restricted antigen presentation , 1989, Nature.

[10]  J. Rothbard,et al.  A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes , 1989, Nature.

[11]  J. Berzofsky Structural basis of antigen recognition by T lymphocytes. Implications for vaccines. , 1988, The Journal of clinical investigation.

[12]  M. Bevan,et al.  Introduction of soluble protein into the class I pathway of antigen processing and presentation , 1988, Cell.

[13]  J. Sissons,et al.  Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses , 1988, The Journal of experimental medicine.

[14]  M. Bevan,et al.  Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides , 1988, The Journal of experimental medicine.

[15]  J. Sissons,et al.  Human cytomegalovirus‐specific cytotoxic T cells: their precursor frequency and stage specificity , 1988, European journal of immunology.

[16]  U. Koszinowski,et al.  CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity , 1987, Journal of virology.

[17]  M. Gething,et al.  Antigen Presentation Pathways to Class I and Class II MHC‐Restricted T Lymphocytes , 1987, Immunological reviews.

[18]  B. Dietzschold,et al.  A synthetic peptide induces long-term protection from lethal infection with herpes simplex virus 2 , 1987, The Journal of experimental medicine.

[19]  B. Jordan,et al.  H—2-restricted cytolytic T cells specific for HLA can recognize a synthetic HLA peptide , 1986, Nature.

[20]  A. McMichael,et al.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides , 1986, Cell.

[21]  A. Geballe,et al.  Regulation of cytomegalovirus late gene expression: gamma genes are controlled by posttranscriptional events , 1986, Journal of virology.

[22]  J. Sissons,et al.  Cytomegalovirus - its cellular immunology and biology. , 1986, Immunology today.

[23]  J. Davey,et al.  Cytotoxic T cells recognize fragments of the influenza nucleoprotein , 1985, Cell.

[24]  S. Jonjić,et al.  Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs , 1985, Journal of virology.

[25]  K. Welte,et al.  A 64,000 dalton matrix protein of human cytomegalovirus induces in vitro immune responses similar to those of whole viral antigen. , 1985, Journal of immunology.

[26]  A. Riggs,et al.  Cloning and physical mapping of a gene fragment coding for a 64-kilodalton major late antigen of human cytomegalovirus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Manischewitz,et al.  HLA-restricted cytotoxic T lymphocytes are an early immune response and important defense mechanism in cytomegalovirus infections. , 1984, Reviews of infectious diseases.

[28]  J. Zaia,et al.  Isolation and partial chemical characterization of a 64,000-dalton glycoprotein of human cytomegalovirus , 1984, Journal of virology.

[29]  U. Koszinowski,et al.  Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection , 1984, Nature.

[30]  L. Gooding,et al.  Recognition by cytotoxic T lymphocytes of cells expressing fragments of the SV40 tumor antigen. , 1983, Journal of immunology.

[31]  L. Borysiewicz,et al.  Human cytomegalovirus‐specific cytotoxic T lymphocytes: requirements for in vitro generation and specificity , 1983, European journal of immunology.

[32]  J. Manischewitz,et al.  Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. , 1982, The New England journal of medicine.

[33]  M. Stinski,et al.  Temporal Patterns of Human Cytomegalovirus Transcription: Mapping the Viral RNAs Synthesized at Immediate Early, Early, and Late Times After Infection , 1982, Journal of virology.

[34]  T. Braciale,et al.  Stimulation of anti-influenza cytolytic T lymphocytes by CNBr cleavage fragments of the viral hemagglutinin. , 1981, Journal of immunology.

[35]  M. Stinski Sequence of protein synthesis in cells infected by human cytomegalovirus: early and late virus-induced polypeptides , 1978, Journal of virology.

[36]  T. Merigan,et al.  Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection. , 1978, The New England journal of medicine.

[37]  P. Neiman,et al.  INTERSTITIAL PNEUMONIA AND CYTOMEGALOVIRUS INFECTION AS COMPLICATIONS OF HUMAN MARROW TRANSPLANTATION1 , 1973, Transplantation.